Tags

Type your tag names separated by a space and hit enter

Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.
Clin Nutr. 2014 Dec; 33(6):1017-23.CN

Abstract

BACKGROUND

Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects.

OBJECTIVE

To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients.

DESIGN

Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated.

RESULTS

Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy (p < 0.001) and protein (p < 0.001) intake compared with control. Compared with baseline, patients receiving the ONS-EPA gained 1.6 ± 5 kg of lean body mass (LBM) compared with a loss of -2.0 ± 6 kg in the control (p = 0.01). Fatigue, loss of appetite and neuropathy decreased in the ONS-EPA group (p ≤ 0.05). There was no difference in response rate or overall survival between groups.

CONCLUSION

Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, loss of appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970).

Authors+Show Affiliations

Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.Neuroimmunology Unit/Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.Cancer Research Unit/Instituto Nacional de Cancerología, Mexico City, Mexico.Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico; Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address: ogar@servidor.unam.mx.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24746976

Citation

Sánchez-Lara, Karla, et al. "Effects of an Oral Nutritional Supplement Containing Eicosapentaenoic Acid On Nutritional and Clinical Outcomes in Patients With Advanced Non-small Cell Lung Cancer: Randomised Trial." Clinical Nutrition (Edinburgh, Scotland), vol. 33, no. 6, 2014, pp. 1017-23.
Sánchez-Lara K, Turcott JG, Juárez-Hernández E, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr. 2014;33(6):1017-23.
Sánchez-Lara, K., Turcott, J. G., Juárez-Hernández, E., Nuñez-Valencia, C., Villanueva, G., Guevara, P., De la Torre-Vallejo, M., Mohar, A., & Arrieta, O. (2014). Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clinical Nutrition (Edinburgh, Scotland), 33(6), 1017-23. https://doi.org/10.1016/j.clnu.2014.03.006
Sánchez-Lara K, et al. Effects of an Oral Nutritional Supplement Containing Eicosapentaenoic Acid On Nutritional and Clinical Outcomes in Patients With Advanced Non-small Cell Lung Cancer: Randomised Trial. Clin Nutr. 2014;33(6):1017-23. PubMed PMID: 24746976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. AU - Sánchez-Lara,Karla, AU - Turcott,Jenny G, AU - Juárez-Hernández,Eva, AU - Nuñez-Valencia,Carolina, AU - Villanueva,Geraldine, AU - Guevara,Patricia, AU - De la Torre-Vallejo,Martha, AU - Mohar,Alejandro, AU - Arrieta,Oscar, Y1 - 2014/04/04/ PY - 2013/11/20/received PY - 2014/01/29/revised PY - 2014/03/18/accepted PY - 2014/4/22/entrez PY - 2014/4/22/pubmed PY - 2015/8/15/medline KW - Eicosapentaenoic acid KW - Health-related quality of life KW - Non-small cell lung cancer KW - Nutritional status SP - 1017 EP - 23 JF - Clinical nutrition (Edinburgh, Scotland) JO - Clin Nutr VL - 33 IS - 6 N2 - BACKGROUND: Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects. OBJECTIVE: To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients. DESIGN: Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated. RESULTS: Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy (p < 0.001) and protein (p < 0.001) intake compared with control. Compared with baseline, patients receiving the ONS-EPA gained 1.6 ± 5 kg of lean body mass (LBM) compared with a loss of -2.0 ± 6 kg in the control (p = 0.01). Fatigue, loss of appetite and neuropathy decreased in the ONS-EPA group (p ≤ 0.05). There was no difference in response rate or overall survival between groups. CONCLUSION: Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, loss of appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970). SN - 1532-1983 UR - https://www.unboundmedicine.com/medline/citation/24746976/Effects_of_an_oral_nutritional_supplement_containing_eicosapentaenoic_acid_on_nutritional_and_clinical_outcomes_in_patients_with_advanced_non_small_cell_lung_cancer:_randomised_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(14)00081-8 DB - PRIME DP - Unbound Medicine ER -